Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bernard Drexinger

Neurology Cumming, GA Medical Doctor

NPI 1407849888 CMS profile 64031

210 Dahlonega St Ste 100, Cumming, GA 30040

Open in the dashboard

General payments

$5,493

294 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bernard Drexinger of Cumming, GA is reported in the CMS Open Payments database as having received $5,493 across 294 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,698 79
2024 General $786 42
2023 General $600 25
2022 General $626 39
2021 General $762 43
2020 General $414 26
2019 General $607 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bernard Drexinger
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Bernard Drexinger were reported at $1,698. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Bernard Drexinger Neurology median Middle half National median
2019 $607 $474 $118–$2,177 $163
2020 $414 $367 $82–$2,309 $114
2021 $762 $438 $104–$2,547 $132
2022 $626 $442 $103–$2,388 $149
2023 $600 $464 $119–$2,312 $160
2024 $786 $468 $119–$2,323 $164
2025 $1,698 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $659 45 payments
  2. Pfizer Inc. $428 28 payments
  3. Teva Pharmaceuticals USA, Inc. $317 11 payments
  4. US WorldMeds, LLC $278 13 payments
  5. Amneal Pharmaceuticals LLC $252 14 payments
  6. Harmony Biosciences LLC $236 7 payments
  7. UCB, Inc. $232 12 payments
  8. Avadel CNS Pharmaceuticals, LLC $200 1 payment
  9. CSL Behring $196 12 payments
  10. Biogen, Inc. $177 8 payments
  11. Other $2,519 143 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,173 289 payments
  2. Consulting Fee $200 1 payment
  3. Education $100 3 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19 1 payment
Products named General payments · program years 2019–2025
  1. QULIPTA $393 33 payments
  2. NURTEC ODT $278 19 payments
  3. UBRELVY $248 18 payments
  4. Austedo XR $224 6 payments
  5. ZAVZPRET $214 15 payments
  6. RYTARY $213 12 payments
  7. LUMRYZ $200 1 payment
  8. Hizentra $196 12 payments
  9. Gocovri $182 7 payments
  10. VYEPTI $121 5 payments
  11. Other $4,009 221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 72 drugs

Part D claims

2,487

Median for Neurology: 833

Drug cost

$154,423

Median for Neurology: $202,670

Branded share of claims

27.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gocovri Amantadine Hcl Brand 13 $43,758
Briviact Brivaracetam Brand 12 $15,967
Keppra Levetiracetam Brand 17 $14,259
Vimpat Lacosamide Brand 11 $11,347
Depakote Er Divalproex Sodium Brand 11 $8,621
Rytary Carbidopa/Levodopa Brand 11 $8,091
Depakote Sprinkle Divalproex Sodium Brand 11 $5,105
Rasagiline Mesylate Generic 35 $5,035
Dilantin Phenytoin Sodium Extended Brand 13 $4,835
Levetiracetam Generic 110 $3,113

The 10 drugs with the highest cost, of 72 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$144,592

Medicare's payments for the services billed

Medicare patients

600

Average age 74

Services billed

3,523

313 women, 287 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 67%
Ischemic heart disease 35%
Diabetes 33%
Chronic kidney disease 30%
Depression 30%
Atrial fibrillation 23%
Heart failure 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Gocovri
  • US WorldMeds, LLC $152
$152 13 —
NURTEC ODT
  • PFIZER INC. $99
$99 — —
VYEPTI
  • Lundbeck LLC $69
$69 — —
ZAVZPRET
  • PFIZER INC. $62
$62 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

294 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record